库尔库 - 青组合治疗活跃克罗恩病患者:一个回顾性,现实世界的多中心队列研究
Nir Salomon1,2, Maayan Marom3, Safwat Odeh3,4
1Department of Gastroenterology, Sheba Medical Center, Ramat-Gan, Israel.
Frontiers in gastroenterology (Lausanne, Switzerland)
|March 13, 2026
概括
亚利碳化合物受体 (AhR) 激动剂CurQD在克罗恩病 (CD) 患者中显示出超过50%的显著临床和生物标志物反应. 这项现实研究强调了CurQD的有效性,即使是在以前用生物药物治疗的患者中.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 黄素和青 (CurQD) 的组合激活了亚利碳化合物受体 (AhR).
- CurQD对性结肠炎有效,但其对克罗恩病 (CD) 的疗效尚未研究.
- 这项研究调查了CurQD在活跃CD患者中的实际有效性.
研究的目的:
- 评估使用CurQD治疗的克罗恩病患者的临床和生物标志物反应和缓解率.
- 评估CurQD在CD患者中的保留率和安全概况.
- 使用GTEx数据集探索AhR表达在肠轴中的作用.
主要方法:
- 对25名活跃的CD患者进行了回顾性多中心队列研究,这些患者接受了CurQD治疗.
- 主要终点:通过患者报告的结果 (PRO2) 定义的临床缓解在8-12周.
- 二级终点:生物标志物反应/缓解 (便calprotectin - FCP) 和CurQD保留;GTEx数据中的AhRmRNA表达的探索性分析.
主要成果:
- 48%的患者实现了临床缓解 (PRO2得分从15降至4,p<0.001).
- 55%的人实现了生物标志物缓解 (FCP从639减少到138μg/g,p=0.001).
- 84%的响应者在8个月后保持了CurQD;常见的副作用包括头痛和胃肠道不适;一种肝酶升高的病例在剂量减少后得到缓解.
结论:
- 在超过50%的CD患者中,CurQD有效地诱导和维持临床和生物标志物反应/缓解.
- 这是第一个支持CurQD在CD治疗疗效的现实证据,包括生物经验患者.
- 结肠与小肠中的可比AhRmRNA表达不能解释潜在的差异性疗效.
更多相关视频
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
636
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
636
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
593
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
593
01:29Inflammatory Bowel Disease IV: Pharmacological Management
893
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
893
01:29Drugs for Treatment of Ulcerative Colitis in IBD
589
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
589
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
693
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
693
01:30Inflammatory Bowel Disease II: Crohn's Disease
1.4K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.4K